Physician profile
Leonard M Bowen
NPI 1851344048
$1,554.30
in general payments reported to CMS, 2019-2025
19 companies · $160 in 2025
The $160 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2021: $96.46 · 2022: $425 · 2023: $304 · 2024: $445 · 2025: $160.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $524 · Food and Beverage: $384.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $524.08 |
| Food and Beverage | $384.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $711.81 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $174.07 | 2022-2025 | |
| Celgene Corporation | $124.80 | 2019 | |
| Abbvie INC. | $113.84 | 2022 | |
| Sobi, INC | $66.46 | 2023-2025 | |
| Daiichi Sankyo INC. | $54.80 | 2022-2024 | Enhertu |
| Aveo Pharmaceuticals, INC. | $49.57 | 2022-2023 | Fotivda |
| Janssen Biotech, INC. | $39.95 | 2022-2024 | Rybrevant |
| Tempus Ai, INC | $39.60 | 2024 | |
| Alexion Pharmaceuticals, INC. | $36.86 | 2022-2024 | Ultomiris |
| Array Biopharma INC | $22.80 | 2022 | |
| Puma Biotechnology, INC. | $20.94 | 2021 | |
| Incyte Corporation | $17.18 | 2025 | Monjuvi |
| Genzyme Corporation | $15.07 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $15.01 | 2023 | Opdivo |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acrotech Biopharma INC. | $13.93 | 2022 | |
| Emd Serono, INC. | $13.84 | 2023 | Bavencio |
| Gilead Sciences, INC. | $11.92 | 2021 | |
| Genentech USA, INC. | $11.85 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leonard Bowen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.